Purdue funneled money to nonprofits, WHO employees to sway opioid guidance: report

Purdue's role in funding nonprofits tied to two WHO opioid prescribing guidelines could implicate the company in other drug dependence crises. (World Health Organization)

Since its inception in 1948, the World Health Organization has sifted through treatment data and posted international prescribing guidelines without an eye on profits. But what happens when a fox is let loose in the henhouse, and that guidance is tainted by private money? That's a question Purdue Pharma may be forced to answer.

Purdue, the maker of powerful and potentially addictive painkillers, funded research front organizations that helped slip language into two WHO opioid guidelines, a bipartisan U.S. House report (PDF) says. That language includes claims “dangerously misleading and, in some instances, outright false,” according to the report spearheaded by Reps. Katherine Clark, D-Massachusetts, and Hal Rogers, R-Kentucky.

The lawmakers linked guidelines that appear to undersell the risks of opioid dependence, particularly in children, to WHO employees and nonprofit organizations with financial ties to Mundipharma, Purdue’s international affiliate. The guidelines were part of an attempt to boost the company’s sales, the report states.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“We are highly troubled that, after igniting the opioid epidemic that cost the United States 50,000 lives in 2017 alone and tens of billions of dollars annually, Purdue is deliberately using the same playbook on an international scale,” the report said.

Clark and Rogers laid out a web of funding among Purdue and eight nonprofits, including the International Association for the Study of Pain, the American Pain Society and the Mayday Fund. All those groups played a role in developing the two guidelines, which were designed to help doctors when treating patients' pain, the report says.

Purdue was also connected to a former WHO employee, William Scholten, a team leader responsible in part for approving the two guidelines, the report alleges. Scholten later became a private consultant and collected speaking fees from Purdue after the guidelines were approved.

Purdue roundly disputed the report’s claims, saying its financial relationships with agencies working with the WHO were aboveboard. And the company downplayed the usefulness of WHO’s guidelines.

“Purdue’s financial support or relationship with third parties are transparent, and any potential conflicts of interest are fully disclosed,” the company said in a statement. “Further, any allegations that Purdue’s financial support and relationships with third parties have violated applicable rules or guidelines are false, and no court or administrative agency has found to the contrary.” 

RELATED: As Purdue settles first opioid case, analysts say the company could face billions in total costs

If the report’s claims are true, they could implicate Purdue in international opioid dependence crises, even as the company faces multiple legal threats stateside. Thousands of U.S. lawsuits link the opioid epidemic to Purdue's aggressive marketing of its painkiller OxyContin, and the company faces scrutiny from federal regulators and prosecutors.

Meanwhile, companies, politicians and nonprofits are distancing themselves from the company and its founding Sackler family. Thursday, JPMorgan cut ties with Purdue, according to CNBC, after the company and its former CEO Richard Sackler were directly implicated in a growing list of lawsuits. The bank gave Purdue six months to find a new home for its cash. Lawmakers including Sen. Elizabeth Warren have donated Sackler family contributions, and museums such as the Metropolitan Museum of Art in New York have returned donations from the family.

In the first state opioid lawsuit to approach trial, Purdue, the Sacklers and the state of Oklahoma reached a $270 million settlement in March to resolve claims the company deceptively marketed its drugs to patients. As part of that deal, the company and members of the Sackler family agreed to fund a new treatment center and cover the state’s litigation expenses.

RELATED: After Oklahoma payout, Purdue faces 5 new state lawsuits over OxyContin

Even with that case closed, Purdue faces an additional 45 state lawsuits that could end in a massive joint settlement. Last week, attorneys general in Iowa, Kansas, Maryland, West Virginia and Wisconsin filed suits of their own against the company and the Sacklers, joining a list of states and cities pursuing payouts of their own.

However, in North Dakota, one lawsuit was knocked down, showing the first crack in states’ attempts to hold Purdue to account. The judge said OxyContin’s FDA labeling, which was targeted in the state’s lawsuit, should be reviewed under federal purview. North Dakota Attorney General Wayne Stenehjem vowed the state would appeal the judge’s dismissal.

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.

Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.